Top

CardioVascular and Interventional Radiology

Published in:

Open Access 01-11-2020 | Metastasis | Clinical Investigation

Intra-hepatic Abscopal Effect Following Radioembolization of Hepatic Metastases

Authors: Maciej Powerski, Ralph Drewes, Jazan Omari, Borna Relja, Alexey Surov, Maciej Pech

Published in: CardioVascular and Interventional Radiology | Issue 11/2020

Abstract

Purpose

To search for abscopal effects (AE) distant to the site of radiation after sequential Yittrium-90 (Y-90) radioembolization (RE) of liver malignancies.

Methods and Materials

In this retrospective analysis, all patients treated by RE between 2007 and 2018 (n = 907) were screened for the following setting/conditions: sequential RE of left and right liver lobe in two sessions, liver-specific MRI (MRI1) acquired max. 10 days before or after first RE (RE1), liver-specific MRI (MRI2) acquired with a minimum time interval of 20 days after MRI1, but before second RE (RE2). No systemic tumor therapies between MRI1 and MRI2. No patients with liver cirrhosis. Metastases > 5 mm in untreated liver lobes were compared in MRI1 and MRI2 and rated as follows: same size or larger in MRI2 = no abscopal effect (NAE); > 30% shrinkage without Y-90 contamination in SPECT/CT = abscopal effect (AE).

Results

Ninety six of 907 patients met aforementioned criteria. Median time-frame between RE1 and MRI2 was 34 (20–64) days. These 96 cases had 765 metastases which were evaluable (median 5(1–40) metastases per patient). Four patients could be identified with at least one shrinking metastasis of the untreated site: one patient with breast cancer (3 metastases: 0 NAE; 3 AE), one patient with prostate cancer (6 metastases: 3 NAE; 3 metastases > 30% shrinkage but possible Y-90 contamination) and two patients with shrinkage of one metastasis each but less than 30%.

Conclusion

Our retrospective study documents AE after RE of liver tumors in 1 out of 96 cases, 3 other cases remain unclear.

Orth M, Lauber K, Niyazi M, Friedl AA, Li M, Maihöfer C, et al. Current concepts in clinical radiation oncology. Radiat Environ Biophys. 2014;53:1–29. https://doi.org/10.1007/s00411-013-0497-2.CrossRefPubMed

Lauber K, Ernst A, Orth M, Herrmann M, Belka C. Dying cell clearance and its impact on the outcome of tumor radiotherapy. Front Oncol. 2012;2:116. https://doi.org/10.3389/fonc.2012.00116.CrossRefPubMedPubMedCentral

Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17:97–111. https://doi.org/10.1038/nri.2016.107.CrossRefPubMed

Di Blasio S, Wortel IMN, van Bladel DAG, de Vries LE, Duiveman-de Boer T, Worah K, et al. Human CD1c(+) DCs are critical cellular mediators of immune responses induced by immunogenic cell death. Oncoimmunology. 2016;5:e1192739. https://doi.org/10.1080/2162402X.2016.1192739.CrossRefPubMedPubMedCentral

Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity. 2013;38:729–41. https://doi.org/10.1016/j.immuni.2013.03.003.CrossRefPubMed

Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1–10. https://doi.org/10.1016/j.immuni.2013.07.012.CrossRefPubMed

Brix N, Tiefenthaller A, Anders H, Belka C, Lauber K. Abscopal, immunological effects of radiotherapy: narrowing the gap between clinical and preclinical experiences. Immunol Rev. 2017;280:249–79. https://doi.org/10.1111/imr.12573.CrossRefPubMed

Filatenkov A, Baker J, Mueller AMS, Kenkel J, Ahn G-O, Dutt S, et al. Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions. Clin Cancer Res. 2015;21:3727–39. https://doi.org/10.1158/1078-0432.CCR-14-2824.CrossRefPubMedPubMedCentral

Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian M, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015;16:795–803. https://doi.org/10.1016/S1470-2045(15)00054-6.CrossRefPubMed

10.

Chandra RA, Wilhite TJ, Balboni TA, Alexander BM, Spektor A, Ott PA, et al. A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology. 2015;4:e1046028. https://doi.org/10.1080/2162402X.2015.1046028.CrossRefPubMedPubMedCentral

11.

Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373–7. https://doi.org/10.1038/nature14292.CrossRefPubMed

12.

Ghodadra A, Bhatt S, Camacho JC, Kim HS. Abscopal effects and yttrium-90 radioembolization. Cardiovasc Intervent Radiol. 2016;39:1076–80. https://doi.org/10.1007/s00270-015-1259-0.CrossRefPubMed

13.

Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol 2006;17:1251–78. https://doi.org/10.1097/01.RVI.0000233785.75257.9A.CrossRefPubMed

14.

Abuodeh Y, Venkat P, Kim S. Systematic review of case reports on the abscopal effect. Curr Probl Cancer. 2016;40:25–37. https://doi.org/10.1016/j.currproblcancer.2015.10.001.CrossRefPubMed

15.

Gorin J-B, Ménager J, Gouard S, Maurel C, Guilloux Y, Faivre-Chauvet A, et al. Antitumor immunity induced after α irradiation. Neoplasia. 2014;16:319–28. https://doi.org/10.1016/j.neo.2014.04.002.CrossRefPubMedPubMedCentral

16.

Hammerl D, Smid M, Timmermans AM, Sleijfer S, Martens JWM, Debets R. Breast cancer genomics and immuno-oncological markers to guide immune therapies. Semin Cancer Biol. 2018;52:178–88. https://doi.org/10.1016/j.semcancer.2017.11.003.CrossRefPubMed

17.

Hennel R, Brix N, Seidl K, Ernst A, Scheithauer H, Belka C, et al. Release of monocyte migration signals by breast cancer cell lines after ablative and fractionated γ-irradiation. Radiat Oncol. 2014;9:85. https://doi.org/10.1186/1748-717X-9-85.CrossRefPubMedPubMedCentral

18.

Denkert C. The immunogenicity of breast cancer–molecular subtypes matter. Ann Oncol. 2014;25:1453–5. https://doi.org/10.1093/annonc/mdu235.CrossRefPubMed

19.

De Velasco MA, Uemura H. Prostate cancer immunotherapy: where are we and where are we going? Curr Opin Urol. 2018;28:15–24. https://doi.org/10.1097/MOU.0000000000000462.CrossRefPubMed

20.

Rödel F, Frey B, Multhoff G, Gaipl U. Contribution of the immune system to bystander and non-targeted effects of ionizing radiation. Cancer Lett. 2015;356:105–13. https://doi.org/10.1016/j.canlet.2013.09.015.CrossRefPubMed

21.

Camphausen K, Moses MA, Ménard C, Sproull M, Beecken W-D, Folkman J, et al. Radiation abscopal antitumor effect is mediated through p53. Cancer Res. 2003;63:1990–3.PubMed

22.

Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys. 2004;60:1552–633. https://doi.org/10.1016/j.ijrobp.2004.09.004.CrossRefPubMed

23.

Bernstein MB, Krishnan S, Hodge JW, Chang JY. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? Nat Rev Clin Oncol. 2016;13:516–24. https://doi.org/10.1038/nrclinonc.2016.30.CrossRefPubMedPubMedCentral

24.

Adashek JJ, Salgia M, Dizman N, Kessler J, Pal SK. Concomitant radioembolization and immune checkpoint inhibition in metastatic renal cell carcinoma. Case Rep Oncol. 2018;11:276–80. https://doi.org/10.1159/000489995.CrossRefPubMedPubMedCentral

25.

Deipolyi AR, Bromberg JF, Erinjeri JP, Solomon SB, Brody LA, Riedl CC. Abscopal effect after radioembolization for metastatic breast cancer in the setting of immunotherapy. J Vasc Interv Radiol. 2018;29:432–3. https://doi.org/10.1016/j.jvir.2017.10.007.CrossRefPubMed

26.

Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity. 2013;39:61–73. https://doi.org/10.1016/j.immuni.2013.07.005.CrossRefPubMedPubMedCentral

27.

Zhan C, Ruohoniemi D, Shanbhogue KP, Wei J, Welling TH, Gu P, et al. Safety of combined Yttrium-90 radioembolization and immune checkpoint inhibitor immunotherapy for hepatocellular carcinoma. J Vasc Interv Radiol. 2020;31:25–34. https://doi.org/10.1016/j.jvir.2019.05.023.CrossRefPubMed

28.

Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009;15:5379–88. https://doi.org/10.1158/1078-0432.CCR-09-0265.CrossRefPubMedPubMedCentral

29.

Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124:687–95. https://doi.org/10.1172/JCI67313.CrossRefPubMedPubMedCentral

30.

Marconi R, Strolin S, Bossi G, Strigari L. A meta-analysis of the abscopal effect in preclinical models: Is the biologically effective dose a relevant physical trigger? PLoS ONE. 2017;12:e0171559. https://doi.org/10.1371/journal.pone.0171559.CrossRefPubMedPubMedCentral

31.

Chen H, Liakou CI, Kamat A, Pettaway C, Ward JF, Tang DN, et al. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci USA. 2009;106:2729–34. https://doi.org/10.1073/pnas.0813175106.CrossRefPubMedPubMedCentral

32.

Patel SP, Woodman SE. Profile of ipilimumab and its role in the treatment of metastatic melanoma. Drug Des Devel Ther. 2011;5:489–95. https://doi.org/10.2147/DDDT.S10945.CrossRefPubMedPubMedCentral

33.

Kang J, Demaria S, Formenti S. Current clinical trials testing the combination of immunotherapy with radiotherapy. J Immunother Cancer. 2016;4:51. https://doi.org/10.1186/s40425-016-0156-7.CrossRefPubMedPubMedCentral

34.

Blankenstein T, Coulie PG, Gilboa E, Jaffee EM. The determinants of tumour immunogenicity. Nat Rev Cancer. 2012;12:307–13. https://doi.org/10.1038/nrc3246.CrossRefPubMedPubMedCentral

Title: Intra-hepatic Abscopal Effect Following Radioembolization of Hepatic Metastases
Authors: Maciej Powerski
Ralph Drewes
Jazan Omari
Borna Relja
Alexey Surov
Maciej Pech
Publication date: 01-11-2020
Publisher: Springer US
Keywords: Metastasis
Breast Cancer
Breast Cancer
Radiotherapy
Published in: CardioVascular and Interventional Radiology / Issue 11/2020
Print ISSN: 0174-1551
Electronic ISSN: 1432-086X
DOI: https://doi.org/10.1007/s00270-020-02612-4

At a glance: The STEP trials

Springer Medicine

Intra-hepatic Abscopal Effect Following Radioembolization of Hepatic Metastases

Abstract

Purpose

Methods and Materials

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods and Materials

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2020

Mission: Impossible?

More Evidence Support PAE: Results of Sham Comparison

Contralateral Dependent Position During Percutaneous CT-Guided Core Needle Biopsy for Small (≤ 20 mm) Lung Lesions Adjacent to the Pericardium: Effect on Procedures and Complications

Histotripsy Ablations in a Porcine Liver Model: Feasibility of Respiratory Motion Compensation by Alteration of the Ablation Zone Prescription Shape

Acute Respiratory Distress Syndrome (ARDS) After Uterine Artery Embolization

Transbrachial Caval Filter Removal: A Simple Alternative